Anti-takeover provisions in our Certificate of Incorporation and Amended and Restated Bylaws
(Bylaws) and under Delaware law, as well as certain existing contractual arrangements, make a third-party acquisition of WMIH difficult.
Our Certificate of Incorporation, including Article VIII thereof, and Bylaws, as well as certain contractual arrangements with KKR & Co.
Inc., (together with its affiliates, KKR), contain provisions that make it difficult for a third party to acquire us, even if doing so might be deemed beneficial by our shareholders. These provisions could limit the price that investors
might be willing to pay in the future for shares of our Common Stock.
We may sell additional shares of our Common Stock or other securities, or amend
our outstanding securities, in the future to meet our capital requirements. In such circumstances, the ownership interests of our shareholders prior to such sale could be substantially diluted.
We have 3,500,000,000 shares of Common Stock authorized for issuance and 10,000,000 shares of preferred stock authorized for issuance. As of
August 15, 2018, we had 1,089,679,818 shares of its Common Stock issued and outstanding. The possibility of dilution posed by shares available for future sale could reduce the market price of our Common Stock and could make it more difficult
for us to raise funds through equity offerings in the future. For example, effective January 30, 2014, we issued 1,000,000 shares of our Series A Preferred Stock, which may be converted into 10,065,629 shares of our Common Stock. The dilutive
effect of the issuance of these shares of Common Stock in the future could adversely affect our Common Stock by causing downward pressure on its market price. For example, if any security holder determines to sell a substantial number of shares of
our Common Stock into the market at any given time, there may not be sufficient demand in the market to purchase the shares without a decline in the market price for our Common Stock. Moreover, continuous sales into the market of a number of shares
in excess of the typical trading volume for our Common Stock could depress the trading market for our Common Stock over an extended period of time. In addition, the fact that our security holders can sell substantial amounts of our Common Stock in
the public market, whether or not sales have occurred or are occurring, could make it more difficult for us to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem
reasonable or appropriate, or at all.
The value of our Common Stock, and our ability to raise capital in the financial markets at times
and at prices favorable to us, may be materially and adversely affected by the future sale of additional shares of our Common Stock or other securities, the future amendment of our outstanding securities, including the Series A Preferred Stock, or
the perception that either of the foregoing could occur or become necessary, and by the terms and conditions of the Series A Preferred Stock, which is senior in priority to our Common Stock.
The dilutive effect of the issuance of shares of our Common Stock pursuant to the terms of the Series B Preferred Stock and in connection with the Merger
could adversely affect our Common Stock by causing downward pressure on its market price and impair our ability to raise capital in the future through the sale of additional equity securities.
Upon the closing of the Merger, all outstanding shares of Series B Preferred Stock were automatically converted into shares of Common Stock and
no Series B Preferred Stock remain outstanding following the closing. As a result, in addition to the 394,209,754 shares of our Common Stock issued as Merger Consideration, (ii) 21,197,619 shares of our Common Stock pursuant to the terms of the
Warrant Exchange Agreement (as defined below), and (iii) 507,936 shares of Common Stock that were issued to each of Mr. Fairfield and Mr. Gallagher, we also issued, pursuant to the terms of the Series B Preferred Stock, 458,591,665 shares
of our Common Stock pursuant to the terms of the Series B Preferred Stock, which includes 444,444,434 shares issued in connection with the mandatory conversion of the Series B Preferred Stock, 11,428,565 shares issued as a special distribution and
2,718,666 shares issued as Dividend Shares. Additionally, 9,652,268 shares of our Common Stock were previously issued as Dividend Shares pursuant to the terms of the Series B Preferred Stock. The issuance of the foregoing shares had a dilutive
effect to our existing shareholders and could adversely affect
24